Free shipping on all orders over $ 500

Ixabepilone

Cat. No. M3768
Ixabepilone Structure
Synonym:

Ixempra, BMS-247550, NSC 710428

Size Price Availability Quantity
5mg USD 240  USD240 In stock
10mg USD 440  USD440 In stock
25mg USD 860  USD860 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ixabepilone (BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound. Ixabepilone induces cell cycle arrest at the G(2)-M phase transition and subsequent apoptotic cell death of MDA-MB-468 (468) cells. Ixabepilone, on a once every 21-day schedule, is modestly active against metastatic gastric cancer previously treated with a taxane. The days 1-5 every 21 days schedule had a more favorable safety profile but no activity. The results of this study suggest that once every 21-day ixabepilone schedule should be pursued further in untreated gastric or gastroesophageal adenocarcinoma patients. Ixabepilone has demonstrated activity in patients with chemotherapy-naive metastatic HRPC. Major toxicities were neutropenia and neuropathy. Further testing to define its activity relative to standard therapy is warranted.

Chemical Information
Molecular Weight 506.7
Formula C27H42N2O5S
CAS Number 219989-84-1
Solubility (25°C) DMSO
Storage 2-8°C, protect from light
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Kim YH, et al. Cancer Chemother Pharmacol. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.

[2] Roché H, et al. Clin Breast Cancer. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.

[3] Huang H, et al. Clin Cancer Res. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Related Microtubule Products
P34cdc2 Kinase Fragment

P34cdc2 Kinase Fragment is associated with the completion of DNA replication in yeast mitosis.

Cemadotin

Cemadotin (LU103793) is an analogue of Dolastatin 15 which is naturally occurring cytotoxic peptides.

VLS-1488

VLS-1488 is an orally active KIF18A inhibitor that inhibits KIF18A microtubule-dependent ATPase activity with an IC50 value of 0.016 μM.

ENMD-1198

ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity.

Tubulin/JAK2-IN-1

Tubulin/JAK2-IN-1 is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ixabepilone, Ixempra, BMS-247550, NSC 710428 supplier, Microtubule, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.